pharma · Pulmonary Arterial Hypertension · Iron Deficiency Anemia · KROS
Keros Therapeutics
Keros Therapeutics patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2021
- Employees
- 10
- Programs
- 3
- Drugs
- 2
- Patents
- 12
Keros Therapeutics patents
12 pharmaceutical patents indexed for Keros Therapeutics. 0 expire within 24 months.
Keros Therapeutics has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12404313
GDNF fusion polypeptides and methods of use thereof
granted -
US 12364737
Activin receptor type IIA variants and methods of use thereof
granted -
US 12350313
Activin receptor type IIa variants and methods of use thereof
granted -
US 12331124
ALK2 antibodies and methods of use thereof
granted -
US 12269858
Activin receptor type IIB variants and methods of use thereof
granted -
US 12071438
Crystal forms of an ALK2 inhibitor
granted -
US 11912750
GDNF fusion polypeptides and methods of use thereof
granted -
US 11884715
Activin receptor type IIB variants and methods of use thereof
granted -
US 11717558
Nucleic acid molecules encoding activin receptor type IIA variants
granted -
US 11484573
Activin receptor type IIa variants and methods of use thereof
granted -
US 11090361
Activin receptor type IIa variants and methods of use thereof
granted -
US 11013785
Activin receptor type IIA variants and methods of use thereof
granted
Frequently asked questions
How many patents does Keros Therapeutics have?
12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Keros Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.